surmount-1 trial tirzepatide obesity without diabetes weight loss once weekly for the treatment of in people with type 2 (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 SURMOUNT-1: Tirzepatide Drastically Reduces Weight

the precise combined metabolic effects of simultaneous GLP-1, GIP, and glucagon receptor activation in humans are still being characterised

Critical Safety Considerations: Thyroid Monitoring With GLP-1 Therapy Before starting semaglutide, anyone with hypothyroidism should have current thyroid function tests (TSH and free T4) confirming stable hormone replacement on their current levothyroxine dose

[DOI] [PubMed] [Google Scholar] 14.Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., Downward J

Since muscle plays a vital role in metabolism and physical function, preserving it should be a top priority

Many factors, such as pre-existing health conditions or other medications, could also explain these symptoms

This shift is propelled by a convergence of scientific validation, celebrity endorsements, and a broader consumer pivot toward proactive, systemic health management that extends beyond basic nutrition